Agreement Builds on Existing Strategic Partnership for Global
ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of
outsourced development services to the pharmaceutical, biotechnology and
medical device industries, today announced that it has been chosen by
Bristol-Myers Squibb Company (NYSE:BMY) as a preferred provider for
full-service clinical pharmacology and exploratory clinical studies.
This latest agreement with Bristol-Myers-Squibb follows the company's
selection of ICON to provide global support for Bristol-Myers-Squibb's
clinical development pipeline, which was announced in June 2010.
Under the preferred provider agreement for early phase development, ICON
will provide a broad range of clinical pharmacology and exploratory
clinical trial services including study conduct in ICON's Clinical
Pharmacology Units, located in San Antonio, Texas; Omaha, Nebraska; and
Manchester, UK. ICON will also provide all supporting scientific
services such as protocol design and development, project management,
clinical monitoring, medical monitoring / pharmacovigilence, data
management, biostatistics, pharmacokinetics and medical writing.
"We are pleased that Bristol-Myers-Squibb has again chosen ICON to bring
greater operational efficiencies and high quality science to their drug
development programs," commented Dr. Mario Rocci, President, ICON
Development Solutions. "Both companies already have a very successful
global partnership for phase II-IV clinical development and central
laboratory services and we look forward to demonstrating the same value
and efficiencies to Bristol-Myers-Squibb's early phase clinical
programs. Our global network of clinical research units, scientists and
project teams, underpinned by world class technology, will drive
significant cost savings and productivity."
About ICON plc
ICON plc is a global provider of outsourced
development services to the pharmaceutical, biotechnology and medical
device industries. The Company specialises in the strategic development,
management and analysis of programs that support clinical development -
from compound selection to Phase I-IV clinical studies. ICON currently
has approximately 7,800 employees, operating from 77 locations in 39
Further information is available at www.iconplc.com
DISCLOSURE NOTICE: The information contained in this release
is as of August 29, 2011. ICON assumes no obligation to update
forward-looking statements contained in this release as a result of new
information or future events or developments.
This release contains forward-looking information about ICON's
strategic partnership with Bristol-Myers Squibb Company, including the
potential benefits of the partnership on ICON's future financial results
and condition that involves substantial risks and uncertainties. These
risks and uncertainties include, among other things, the risk that the
partnership results in more limited provision of services by ICON than
expected, that those services do not have the expected financial impact
on ICON or that the partnership is terminated.
A further description of risks and uncertainties can be found in
ICON's Annual Report on Form 20-F for the fiscal year ended December 31,
2010 and in its Reports of Foreign Issuer on Form 6-K filed with the US
Securities and Exchange Commission.
VP Investor Relations
(0)20 7067 0190
Source: ICON plc
News Provided by Acquire Media